Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Published:2024-10 Issue: Volume:145 Page:107565
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Desai Amrita,Samara Yazeed,Yang Dongyun,Ball Brian,Braun Adam,Koller Paul,Blackmon Amanda,Agrawal Vaibhav,Pourhassan Hoda,Amanam Idoroenyi,Arslan Shukaib,Otoukesh Salman,Sandhu Karamjeet,Aldoss Ibrahim,Ali Haris,Salhotra Amandeep,Al Malki Monzr M.,Artz Andrew,Becker Pamela,Smith Eileen,Stein Anthony,Marcucci Guido,Forman Stephen J.,Curtin Peter,Nakamura Ryotaro,Pullarkat Vinod

Publisher

Elsevier BV

Reference25 articles.

1. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators;Qiu;RNA,2016

2. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance;Patnaik;Am. J. Hematol.,2013

3. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes;Haferlach;Leukemia,2014

4. Malcovati L., Stevenson K., Papaemmanuil E., et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS [published correction appears in Blood. 2021 May 27;137(21):3003]. Blood. 2020;136(2):157-170. doi:10.1182/blood.2020004850.

5. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes;Bersanelli;J. Clin. Oncol.,2021